BioSpace News Archive

Rezolute, Inc., a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to chronic glucose imbalance, has been added to the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28.

Rockwell Medical, Inc. announced that it has submitted a pre-IND meeting request with the U.S. Food and Drug Administration in support of its proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate, designed for the treatment of iron deficiency anemia and maintenance of hemoglobin in patients receiving infusion therapy in the home setting.

Renalytix plc announces new data demonstrating KidneyIntelX™ can be effective at monitoring therapeutic response and improvements in kidney health over time in adults with type 2 diabetes.

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, announced key clinical and regulatory updates across its pipeline.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced preliminary results of a new preclinical study showing potent inhibition of COVID-19 variants of concern by opaganib.

Private Equity group Siparex, Paris, has taken a minority stake in Pharmactive , a company specializing in the research, development, and extraction of branded natural ingredients.

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that the U.S. Food and Drug Administration has granted Fast Track Designation to SNDX-5613 for the treatment of adult and pediatric patients with relapsed or refractory acute leukemias harboring a mixed lineage leukemia rearranged or nucleophosmin mutation.

Danimer Scientific today announced the results of its redemption of its warrants (the “Public Warrants”) to purchase shares of its common stock, $0.0001 par value per share.

Precision BioSciences, Inc. and SpringWorks Therapeutics, Inc. announced that the first patient has been dosed in the combination arm of Precision’s Phase 1/2a trial evaluating PBCAR269A.

Kiromic is being recognized as a pioneer of immuno oncology with a presentation at the 4th Annual Next-Gen Immuno Oncology Congress in June 2021.